



NDA 017823/S-024

APPROVAL LETTER

Sun Pharmaceutical Industries, Inc.
Attention: Ronak Patel
Senior Manager, Regulatory & Business Continuity
2 Independence Way
Princeton, NJ 08540

Dear Mr. Patel:

Please refer to your Supplemental New Drug Application (sNDA) dated and received March 29, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Halog (halcinonide) Solution USP, 0.1%.

We acknowledge receipt of your amendment dated November 22, 2019, which constituted a complete response to our July 29, 2019, action letter.

This Prior Approval supplemental new drug application provides for multiple changes concerning the drug product and the drug substance, as follows:

- Addition of (b) (4) (FEI: (b) (4)) as a new drug product manufacturing and packaging site
- Addition of (b) (4) (FEI: (b) (4)) as a new supplier of the halocinonide drug substance with reference to DMF (b) (4)
- Notification of changes to the drug product manufacturing processes, operation parameters and equipment
- Provision of new suppliers for some of excipients
- Addition of new packaging component suppliers
- The addition of a new package size (120mL)

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling (text for the prescribing

information) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 017823/S-024.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 017823/S-024

Page 3

If you have any questions, call Yajun Jason Tu, Regulatory Business Process Manager, at (240) 402 - 4202.

Sincerely,

{See appended electronic signature page}

David Lewis, Ph.D.
Branch Chief, BII
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling

Carton and Container Labeling



David
Lewis

Digitally signed by David Lewis
Date: 3/18/2020 11:19:38AM
GUID: 508da72000029f287fa31e664741b577